| Aadi Bioscience Relaunches as Whitehawk Therapeutics Marking Evolution into ADC Company |
New name reflects focus on accelerating portfolio of advanced ADC therapies with speed, agility and precision Upon closing of strategic transactions, cash expected to fund operations into 2028 enabling anticipated key clinical data readouts for its ADC assets Company shares to trade on Nasdaq under the symbol "WHWK" effective March 19, 2025 Company reports financial results for the fourth quarter and full-year 2024, and will host a conference call tomorrow, March 19 at 8:30 am ET MORRISTOWN, N.J. , March 18, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), formerly known as Aadi Bioscience, Inc., an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments, today announced it changed its name to Whitehawk Therapeutics, reflecting the Company's evolution and focus on accelerating its portfolio of antibody drug conjugates (ADCs) with speed, agility and precision. |
prnewswire.com |
2025-03-18 18:00:00 |
Czytaj oryginał (ang.) |
| Aadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate Update |
MORRISTOWN, N.J. , March 14, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (Nasdaq: AADI) ("Aadi") today announced that it will host a webcast to discuss fourth quarter and full-year 2024 financial results and provide recent corporate updates on Wednesday, March 19, 2025. |
prnewswire.com |
2025-03-14 10:00:00 |
Czytaj oryginał (ang.) |
| Aadi Bioscience, Inc. (AADI) Expected to Beat Earnings Estimates: Should You Buy? |
Aadi Bioscience (AADI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-03-05 13:00:36 |
Czytaj oryginał (ang.) |
| Aadi Bioscience Announces Closing of $100 Million PIPE Financing |
MORRISTOWN, N.J. , March 4, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (Nasdaq: AADI) ("Aadi"), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver advances in cancer treatment, today announced the closing of its previously announced private placement. |
prnewswire.com |
2025-03-04 18:05:00 |
Czytaj oryginał (ang.) |
| Aadi Bioscience Announces Approval of All Proposals at Special Meeting of Stockholders |
MORRISTOWN, N.J. , March 3, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver advances in cancer treatment, today announced that the Company's stockholders have approved all proposals voted on at the Company's Special Meeting of Stockholders ("Special Meeting") held on February 28, 2025. |
prnewswire.com |
2025-03-03 10:00:00 |
Czytaj oryginał (ang.) |
| All You Need to Know About Aadi Bioscience (AADI) Rating Upgrade to Buy |
Aadi Bioscience (AADI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-02-26 15:00:29 |
Czytaj oryginał (ang.) |
| Aadi Bioscience to Present at the TD Cowen 45th Annual Healthcare Conference |
MORRISTOWN, N.J. , Feb. 24, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) announced today its presentation at the TD Cowen 45th Annual Healthcare Conference, taking place March 3-5, 2025, in Boston, MA. |
prnewswire.com |
2025-02-24 10:00:00 |
Czytaj oryginał (ang.) |
| Aadi Bioscience Appoints David Dornan, PhD, as Chief Scientific Officer |
Seasoned Oncology Leader Brings Extensive ADC Expertise to Support Company's New Pipeline MORRISTOWN, N.J. , Feb. 18, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced the appointment of David Dornan, PhD as the Company's Chief Scientific Officer (CSO). |
prnewswire.com |
2025-02-18 10:00:00 |
Czytaj oryginał (ang.) |
| Aadi Bioscience Filed Definitive Proxy Statement and Schedules Special Meeting of Stockholders for February 28, 2025 |
Proxy Statement Includes Proposals on Previously Announced Sale of FYARRO and Associated Infrastructure to Kaken for $100M, and $100M PIPE Financing to Support In-Licensing of ADC Portfolio Aadi's Board Recommends Stockholders Vote "FOR" All Proposals to Support the Company's Business Transformation Company Expects to Close Transactions in the First Quarter of 2025, Subject to Stockholder Approval and Other Closing Conditions MORRISTOWN, N.J. , Feb. 5, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) ("Aadi" or the "Company") announced it filed its definitive proxy statement with the U.S. Securities and Exchange Commission (the "SEC") on January 31, 2025, and today mailed its definitive proxy statement and a letter to stockholders, in connection with the Company's upcoming Special Meeting of Stockholders (the "Special Meeting") which is scheduled to be held on February 28, 2025. |
prnewswire.com |
2025-02-05 18:05:00 |
Czytaj oryginał (ang.) |
| Why Is Cancer-Focused Aadi Bioscience Stock Trading Higher On Friday? |
On Thursday, Aadi Bioscience, Inc. AADI entered into an exclusive license agreement for the development and global commercialization of a three-asset portfolio of preclinical antibody-drug conjugates (ADCs), in collaboration with WuXi Biologics and Hangzhou DAC Biotechnology Co., Ltd. |
benzinga.com |
2024-12-20 10:43:35 |
Czytaj oryginał (ang.) |
| Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing |
Aadi Enters into Exclusive License for Three-Asset ADC Portfolio Developed through a Collaboration between WuXi Biologics and HANGZHOU DAC Aadi Enters Agreement to Sell FYARRO® and Associated Infrastructure to KAKEN Pharmaceutical for $100M; Announces PIPE Financing of $100M Cumulative Capital Expected to Fund Operations into Late 2028, Including Anticipated Clinical Data for the ADC Portfolio Co-Founder and Former CEO of ProfoundBio, Baiteng Zhao, Appointed to Aadi Board of Directors Aadi to Hold Webcast and Conference Call on December 20 at 8:00 AM EST LOS ANGELES , Dec. 19, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced it has entered into an exclusive license agreement for development and global commercialization of a three-asset portfolio of preclinical, next-wave antibody-drug conjugates (ADCs), in collaboration with WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and HANGZHOU DAC BIOTECHNOLOGY CO., LTD. (HANGZHOU DAC), a global leader in ADC innovation. |
prnewswire.com |
2024-12-19 20:30:00 |
Czytaj oryginał (ang.) |
| Aadi Bioscience, Inc. (AADI) Reports Q3 Loss, Tops Revenue Estimates |
Aadi Bioscience, Inc. (AADI) came out with a quarterly loss of $0.46 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.60 per share a year ago. |
zacks.com |
2024-11-06 12:10:53 |
Czytaj oryginał (ang.) |
| Aadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate Update |
FYARRO® sales of $7.2 million for Q3 2024, reflecting 21% year over year sales growth Aadi continues to focus on FYARRO commercial business and comprehensive strategic review to maximize shareholder value LOS ANGELES , Nov. 6, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced financial results for the third quarter ended September 30, 2024, and provided recent corporate progress. "The third quarter saw strong sales growth for FYARRO, backed by continued account momentum, increased demand and a nearly 90 percent reorder rate – all reinforcing the clinical value of FYARRO for patients with advanced malignant PEComa," said Dave Lennon, President and CEO of Aadi Bioscience. |
prnewswire.com |
2024-11-06 10:00:00 |
Czytaj oryginał (ang.) |
| Aadi Bioscience to Report Third Quarter 2024 Results and Corporate Update |
LOS ANGELES, Oct. 30, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced that it will report third quarter 2024 financial results and provide recent corporate updates on Wednesday, November 6, 2024. These results will be available under the "Investors & News" page of the Aadi Bioscience website at aadibio.com. |
prnewswire.com |
2024-10-30 18:05:00 |
Czytaj oryginał (ang.) |
| Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates |
PRECISION1 tumor-agnostic trial unlikely to meet regulatory threshold to support an accelerated approval and will be halted Aadi will focus on FYARRO® commercial business for its approved indication, PEComa, and conduct a comprehensive strategic review to maximize shareholder value To further preserve cash position, Aadi will adjust ongoing Phase 2 trials and reduce R&D headcount by 80%, thereby extending cash runway into at least 2H 2026 LOS ANGELES , Aug. 20, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced it will halt the registration-intended PRECISION1 trial of nab-sirolimus in patients with solid tumors harboring TSC1 or TSC2 inactivating alterations. An analysis by the Independent Data Monitoring Committee demonstrated that the study was unlikely to exceed an efficacy threshold necessary to support an accelerated approval, the key goal of this Phase 2 study. |
prnewswire.com |
2024-08-20 21:00:00 |
Czytaj oryginał (ang.) |
| Aadi Bioscience, Inc. (AADI) Q2 2024 Earnings Call Transcript |
Aadi Bioscience, Inc. (NASDAQ:AADI ) Q2 2024 Earnings Conference Call August 7, 2024 8:30 AM ET Company Participants David Lennon - President and Chief Executive Officer Scott Giacobello - Chief Financial Officer, Investor Relations and Corporate Communications Loretta Itri - Chief Medical Officer Conference Call Participants Roger Song - Jefferies Joseph Catanzaro - Piper Sandler Ahu Demir - Ladenburg Thalmann Operator Good day and thank you for standing by. Welcome to the Aadi Bioscience Inc. Second Quarter 2024 Earnings Call. |
seekingalpha.com |
2024-08-10 14:20:25 |
Czytaj oryginał (ang.) |
| Aadi Bioscience, Inc. (AADI) Reports Q2 Loss, Lags Revenue Estimates |
Aadi Bioscience, Inc. (AADI) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to loss of $0.67 per share a year ago. |
zacks.com |
2024-08-07 14:11:58 |
Czytaj oryginał (ang.) |
| Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update |
FYARRO® sales of $6.2 million for Q2 2024, a 15% quarter over quarter sales growth Interim analysis of two-thirds of fully enrolled PRECISION1 trial planned for Q3 2024 Conference call to be held today at 8:30 am EDT LOS ANGELES , Aug. 7, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced financial results for the second quarter ended June 30, 2024, and highlighted recent corporate progress. "The second quarter saw quarter over quarter sales growth for FYARRO, as anticipated, and an increase in demand across both new and existing accounts, including from major oncology centers. |
prnewswire.com |
2024-08-07 12:00:00 |
Czytaj oryginał (ang.) |
| Aadi Bioscience to Report Second Quarter 2024 Results and Corporate Update |
Company to Host Conference Call and Webcast on August 7, 2024 LOS ANGELES , July 31, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced that it will host a conference call and live webcast on Wednesday, August 7, 2024, at 8:30 am EDT (5:30 am PDT) to report second quarter 2024 financial results and provide recent corporate updates. Conference Call Information Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at aadibio.com. |
prnewswire.com |
2024-07-31 20:05:00 |
Czytaj oryginał (ang.) |
| 3 Russell 2000 Stocks to Sell in July Before They Crash & Burn |
One of many stock market indexes used to measure performance, the Russell 2000 is composed of 2,000 small-cap companies that make up the bottom two-thirds of the Russell 3000 index. The reason is that the top 1,000 stocks in the Russell 3000 make up 93% of the index's market cap, so focusing on the lower 2,000 allows analysts and investors to judge the movement of the small-cap market more accurately. |
investorplace.com |
2024-07-05 17:07:29 |
Czytaj oryginał (ang.) |
| Aadi Bioscience to Participate in the Jefferies Healthcare Conference |
LOS ANGELES , May 29, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, announced today participation in the Jefferies Healthcare Conference, taking place June 5-6, 2024, in New York. Dave Lennon, Ph.D. |
prnewswire.com |
2024-05-29 20:05:00 |
Czytaj oryginał (ang.) |
| Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting |
nab-Sirolimus demonstrated significantly greater intratumoral drug concentration, stronger inhibition of mTOR targets and greater antitumor activity compared to IV and oral mTOR inhibitors in a xenograft model Data support further clinical exploration of nab-sirolimus as a single agent or in combination LOS ANGELES , May 23, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced new nonclinical data demonstrating the significantly higher intratumoral drug concentration, stronger inhibition of mTOR targets and greater antitumor activity of nab-sirolimus compared to intravenous and oral mTOR inhibitors in a xenograft model. These data will be available as an abstract and published in the Journal of Clinical Oncology supplement to coincide with the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4, 2024. |
prnewswire.com |
2024-05-23 21:30:00 |
Czytaj oryginał (ang.) |
| Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update |
Fully enrolled registration-intended PRECISION1 trial; two-thirds interim analysis planned for Q3 2024 FYARRO® sales of $5.4 million for Q1 2024, reflects distributor ordering patterns and fewer commercial patient initiations at the start of the year Conference call to be held today at 8:30 am EDT LOS ANGELES , May 8, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress. "I'm pleased to announce that PRECISION1 is now fully enrolled across a broad array of tumor types and our promising development plan continues to gain momentum. |
prnewswire.com |
2024-05-08 12:00:00 |
Czytaj oryginał (ang.) |
| Aadi Bioscience to Report First Quarter 2024 Results and Corporate Update |
Company to Host Conference Call and Webcast on May 8, 2024 LOS ANGELES , May 1, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced that it will host a conference call and live webcast on Wednesday, May 8, 2024 at 8:30 am EDT (5:30 am PDT) to report first quarter 2024 financial results and provide recent corporate updates. Conference Call Information Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at aadibio.com. |
prnewswire.com |
2024-05-01 12:01:00 |
Czytaj oryginał (ang.) |
| Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting |
Data further support clinical exploration of nab-sirolimus in combination with endocrine therapy for hormone-driven cancers, as is currently being investigated for patients with endometrioid-type endometrial cancer in a Phase 2 trial Data highlight potential for synergy to enhance anti-cancer effects and overcome resistance in non-small cell lung cancer LOS ANGELES , April 9, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced it will present new non-clinical data that highlight the combinability of nab-sirolimus and its potential for synergy to enhance anti-cancer effects and overcome resistance. These data will be presented during poster sessions at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, taking place April 5-10, 2024. |
prnewswire.com |
2024-04-09 12:00:00 |
Czytaj oryginał (ang.) |
| Is Aadi Bioscience (AADI) Stock Outpacing Its Medical Peers This Year? |
Here is how Aadi Bioscience, Inc. (AADI) and Amplifon S.p.A. (AMFPF) have performed compared to their sector so far this year. |
zacks.com |
2024-04-03 14:46:41 |
Czytaj oryginał (ang.) |
| Is Aadi Bioscience (AADI) Outperforming Other Medical Stocks This Year? |
Here is how Aadi Bioscience, Inc. (AADI) and Amplifon S.p.A. (AMFPF) have performed compared to their sector so far this year. |
zacks.com |
2024-03-18 12:45:43 |
Czytaj oryginał (ang.) |
| Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO) |
Subgroup experienced efficacy and safety consistent with overall study population Advanced malignant PEComa tumors of gynecologic origin accounted for more than half of the evaluable patients enrolled in AMPECT Additional data presented highlight nab-sirolimus as potential approach for mTOR-driven gynecologic cancers LOS ANGELES , March 17, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced patients in the AMPECT trial whose malignant perivascular epithelioid cell tumor (PEComa) had gynecologic origins experienced efficacy and safety consistent with the overall study population. The AMPECT trial formed the basis for the FDA approval of the company's nab-sirolimus, FYARRO®, for advanced malignant PEComa regardless of mutational status. |
prnewswire.com |
2024-03-17 10:00:00 |
Czytaj oryginał (ang.) |
| Aadi Bioscience, Inc. (AADI) Q4 2023 Earnings Call Transcript |
Aadi Bioscience, Inc. (AADI) Q4 2023 Earnings Call Transcript |
seekingalpha.com |
2024-03-13 13:43:10 |
Czytaj oryginał (ang.) |